Pancreatic cancer patients will now have remote access to precision nutrition testing thanks to a new partnership

Integration of xCures and Vault Health Creates a Decentralized Platform to Benefit Pancreatic Cancer Research and Facilitates Enrollment in Faeth’s NEAAR-001 Study

By enabling remote access to the NEAAR-001 study, a broader subset of patients can enroll in our trial without having to leave their homes, regardless of where they live.”

— Anand Parikh – co-founder and CEO of Faeth

OAKLAND, CALIFORNIA, USA, Aug. 24, 2022 / — xCures, Inc. is proud to partner with Vault Health, a decentralized workforce research and screening company, to facilitate enrolling pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial of a nutrition-based precision diet that limits specific amino acids that preclinical studies have shown are necessary for cancer growth. The study involves patients with newly diagnosed metastatic pancreatic adenocarcinoma who are to receive chemotherapy treatment with gemcitabine and abraxane.

Vault Health’s decentralized research capabilities will allow Faeth to expand the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. By combining xCures’ record collection, virtual screening, electronic consent and data structuring technology with Vault Health’s suite of cutting-edge patient-centric clinical research services, including telemedicine, remote samples and logistics, the NEAAR-001 protocol can be delivered directly to patients in the comfort of their homes.

“We are thrilled to partner with Vault Health and Faeth Therapeutics to help patients with newly diagnosed pancreatic cancer gain access to the NEAAR-001 study as a decentralized, patient-centered clinical trial,” said said Mika Newton, CEO of xCures. “Importantly, our combined efforts will enable cancer patients from diverse populations and socioeconomic backgrounds to participate in research.”

“We are excited to bring our patient-centric philosophy to simplify the journey and offer clinical research as a care option for patients with pancreatic cancer,” said Alexander Pastuszak, MD, PhD, president of clinical care. and Medical and Scientific Director, Vault Health. “With xCures and Faeth Therapeutics, we look forward to rapidly recruiting and enrolling patients where they are, reducing recruitment time and costs, and increasing patient engagement.”

“Faeth is dedicated to curing every cancer for every patient, and this partnership with Vault Health and xCures will make it easier for many more people with metastatic pancreatic cancer to access our precision nutrition intervention,” said Faeth co-founder and CEO Anand Parikh. “Faeth wants to provide access to our clinical trials to a broader subset of patients, and by enabling remote access to the NEAAR-001 study, they can enroll in our trial without having to leave their domicile, regardless of their place of residence. “

About xCures
xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal experimental or approved therapies. The platform’s portals, xINFORM for patients and xDECIDE for providers, present the scientific and medical justifications for the options offered and a clear picture of a patient’s medical records and history. The platform prospectively generates concrete evidence for clinical studies and decentralized trials. For more information, contact or visit

About the vault
Vault is at the forefront of simplifying the execution of decentralized and hybrid clinical trials and delivering the highest quality patient experience, supported by cutting-edge technology and virtual care. Vault’s mission is to accelerate better health outcomes through faster diagnosis, innovative clinical research, and digital-first care delivery. Vault works with more than 3,000 world-class customers – including business, public health, education, pharmaceutical and biotech – to deliver care to their populations. Learn more:

about faith
Faeth Therapeutics is a cancer metabolism company that develops clinically tested nutritional controls, therapies and digital tools for the treatment of cancer. Founded in 2019 by leading researchers in Europe and the United States and backed by leading investors, the company is pioneering its work on cancer metabolism to support a radically new way of treating cancer. Faeth’s research, published in peer-reviewed scientific journals, shows that tailoring the right diet to the cancer patient can have a significant impact on the effectiveness of clinically tested cancer therapies. Feed the fight. For more information:

Patrick van der Valk
xCures Inc.
+1 415-692-5258
Visit us on social media:


Leave a Comment